35. 天疱瘡 ［臨床試験数：57，薬物数：81（DrugBank：36），標的遺伝子数：17，標的パスウェイ数：149］
Searched query = "Pemphigus"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/21/2019, 11/20/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04023149 | August 10, 2019 | 29 July 2019 | Efficacy of Interleukin-2 Gargle in the Treatment of Oral Mucosa Lesion in Pemphigus Vulgaris | Short-term Efficacy of Interleukin-2 Gargle Combined With Systemic Use of Glucocorticoids in the Treatment of Oral Mucosal Lesion in Pemphigus Vulgaris: a Randomized, Controlled, Double-blind, Multicenter Clinical Study | Pemphigus Vulgaris | Drug: recombinant human interleukin-2 (rhIL-2);Drug: placebo | Second Xiangya Hospital of Central South University | Not recruiting | 18 Years | 60 Years | All | 180 | Phase 2 | China | |
| 2 | NCT03780166 | March 2019 | 30 September 2019 | A Study of the Safety and Tolerability of INCB050465 in Pemphigus Vulgaris | A Phase 2 Dose-Escalation Study of the Safety and Tolerability of INCB050465 in Participants With Pemphigus Vulgaris | Pemphigus Vulgaris | Drug: Parsaclisib | Incyte Corporation | Not recruiting | 18 Years | 80 Years | All | 0 | Phase 2 | ||
| 3 | EUCTR2018-002261-19-ES | 08/02/2019 | 28 February 2019 | A study to evaluate the efficacy and safety of PRN1008 in patients with pemphigus | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Oral BTK Inhibitor PRN1008 in Moderate to Severe Pemphigus | pemphigus vulgaris [PV] or pemphigus foliaceus [PF] MedDRA version: 20.0 Level: LLT Classification code 10052802 Term: Pemphigus vulgaris System Organ Class: 100000004858 MedDRA version: 20.0 Level: LLT Classification code 10057054 Term: Pemphigus foliaceous System Organ Class: 100000004858 ;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] | Product Name: PRN1008 Product Code: PRN1008 Pharmaceutical Form: Tablet INN or Proposed INN: not available CAS Number: 1575596 Current Sponsor code: PRN1008 Other descriptive name: PRN1008 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 400- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use | Principia Biopharma | Authorised | Female: yes Male: yes | 120 | Phase 3 | Serbia;United Arab Emirates;United States;Taiwan;Greece;Spain;Ukraine;Turkey;Israel;Italy;United Kingdom;France;Canada;Poland;Croatia;Australia;Bulgaria;Germany | |||
| 4 | NCT03762265 | January 8, 2019 | 11 November 2019 | A Study of PRN1008 in Patients With Pemphigus | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Oral BTK Inhibitor PRN1008 in Moderate to Severe Pemphigus | Pemphigus | Drug: PRN1008 Oral Tablet;Drug: Placebo Oral Tablet | Principia Biopharma Inc. | Recruiting | 18 Years | 80 Years | All | 120 | Phase 3 | United States;Australia;Bulgaria;Canada;France;Germany;Greece;Israel;Italy;Poland;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom | |
| 5 | ChiCTR1800020382 | 2019-01-01 | 14 January 2019 | Efficacy and safety of ultra-low dosage regimen of rituximab combined with corticosteroids in the treatment of pemphigus | Efficacy and safety of ultra-low dosage regimen of rituximab combined with corticosteroids in the treatment of pemphigus | Pemphigus | Group 1:Rituximab 500mg single infusion combined with routinedose of corticosteriods therapy;Group 2:Rituximab 100mg single infusion combined with routinedose of corticosteriods therapy;Group 3:Oral or intravenous infusion of routinedose of corticosteriods (prednisone or methylprednisolone); | West China Hospital, Sichuna University | Recruiting | 18 | 80 | Both | Group 1:14;Group 2:14;Group 3:14; | Pilot study | China | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | JPRN-JapicCTI-184231 | 01/12/2018 | 16 July 2019 | ONO-4059 phase II study | ONO-4059 phase II study: Multicenter, open-label, uncontrolled, single-arm study in patients with refractory pemphigus | Refractory pemphigus | Intervention name : ONO-4059 INN of the intervention : Tirabrutinib Dosage And administration of the intervention : Oral administration | ONO PHARMACEUTICAL CO.,LTD. | Not Recruiting | 20 | BOTH | 14 | Phase 2 | |||
| 7 | JPRN-jRCTs051180069 | 12/04/2018 | 2 April 2019 | Imatinib treatment of autoimmune bullous diseases | Intervention study on autoimmune bullous diseases with imatinib - IABD | Autoimmune bullous disease including pemphigus group and pemphigoid group;D012872 | Imatinib 800 mg a day p.o. for seven days will be started within 14 days of starting steroid therapy (and when the bed is secured). | Kenji Kabashima | Takashi Nomura;Akihiko Kitoh;Tetsuya Honda;Gyohei Egawa;Yuichiro Endo;Yo Kaku;Atsushi Otsuka | Recruiting | 20 years old | One hundred years old | Both | 10 | Phase 0 | none |
| 8 | EUCTR2017-002333-40-DE | 31/01/2018 | 30 April 2019 | A study to evaluate the safety and efficacy of ARGX-113 in patients with Mild to Moderate Pemphigus Vulgaris or Foliaceus) | An Open-label, Non-controlled, Phase II Study to Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, Efficacy and Conditions of Use of ARGX-113 in Patients with Mild to Moderate Pemphigus (Vulgaris or Foliaceus) | Pemphigus (Vulgaris or Foliaceus) MedDRA version: 20.0 Level: LLT Classification code 10052802 Term: Pemphigus vulgaris System Organ Class: 100000004858 MedDRA version: 20.0 Level: LLT Classification code 10057069 Term: Pemphigus foliaceus System Organ Class: 100000004858 ;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] | Product Name: ARGX-113 Product Code: ARGX-113 Pharmaceutical Form: Solution for infusion INN or Proposed INN: efgartigimod CAS Number: 1821402-21-4 Current Sponsor code: ARGX-113 Concentration unit: mg/kg milligram(s)/kilogram Concentration type: equal Concentration number: 25- | argenx BVBA | Authorised | Female: yes Male: yes | 22 | Phase 2 | Hungary;Ukraine;Romania;Israel;Germany;Italy | |||
| 9 | NCT03334058 | October 18, 2017 | 9 September 2019 | A Study to Evaluate the Safety, PD, PK and Efficacy of ARGX-113 in Patients With Pemphigus | An Open-label, Non-controlled, Phase II Study to Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, Efficacy and Conditions of Use of ARGX-113 in Patients With Mild to Moderate Pemphigus (Vulgaris and Foliaceus) | Pemphigus Vulgaris;Pemphigus Foliaceus | Drug: ARGX-113 | argenx BVBA | Recruiting | 18 Years | N/A | All | 12 | Phase 2 | Germany;Hungary;Israel;Italy;Ukraine | |
| 10 | NCT03239470 | October 10, 2017 | 29 July 2019 | Polyclonal Regulatory T Cells (PolyTregs) for Pemphigus | A Phase I, Open-Label, Multicenter Trial Exploring the Safety and Tolerability of Autologous Polyclonal Regulatory T Cell Therapy in Adults With Active Pemphigus (APG01) | Pemphigus Foliaceus;Pemphigus Vulgaris | Biological: Cohort 1: 1.0 x 10^8 PolyTregs;Biological: Cohort 2: 2.5x10^8 PolyTregs | National Institute of Allergy and Infectious Diseases (NIAID) | Autoimmunity Centers of Excellence | Recruiting | 18 Years | 75 Years | All | 12 | Phase 1 | United States |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 11 | NCT03075904 | August 1, 2017 | 14 October 2019 | A Safety and Dose-Finding Study of SYNT001 in Subjects With Pemphigus (Vulgaris or Foliaceus) | A Phase 1b/2, Multicenter, Open-Label, Safety, and Dose-Finding Study of SYNT001 in Subjects With Pemphigus (Vulgaris or Foliaceus) | Pemphigus;Pemphigus Vulgaris;Pemphigus Foliaceus | Drug: SYNT001 | Alexion Pharmaceuticals | Not recruiting | 18 Years | N/A | All | 8 | Phase 1/Phase 2 | United States | |
| 12 | JPRN-jRCTs031180405 | 11/05/2017 | 10 September 2019 | Rituximab therapy for refractory pemphigus | Safety evaluation study about rituximab therapy for refractory pemphigus | Refactory Pemphigus Other disease of skin or skin tissue | Infuse rituximab 1000mg/body twice biweekly. | Takeru Funakoshi | Recruiting | 20 years of age | 80 years of age | Both | 10 | N/A | none | |
| 13 | JPRN-UMIN000026004 | 2017/05/08 | 2 April 2019 | Safety evaluation study about rituximab therapy for refractory pemphigus | pemphigus | Infuse rituximab 1000mg/body twice biweekly | Keio University, School of Medicine | Recruiting | 20years-old | 80years-old | Male and Female | 10 | Not applicable | Japan | ||
| 14 | NCT02993133 | December 2016 | 6 May 2019 | Pharmacokinetics Study of Mycophenolic Acid in Patients With an Autoimmune Bullous Dermatose, Pemphigus or Cicatricial Pemphigoid. | Pharmacokinetics Study of Mycophenolic Acid in Patients With an Autoimmune Bullous Dermatose, Pemphigus or Cicatricial Pemphigoid. | Autoimmune Bullous Dermatose | Drug: Cellcept® in autoimmune bullous dermatoses | University Hospital, Limoges | Not recruiting | 18 Years | N/A | All | 53 | Phase 3 | France | |
| 15 | JPRN-UMIN000024265 | 2016/10/04 | 2 April 2019 | Open-label, single-arm, multicenter, investigators initiated phase II clinical trial to evaluate the efficacy and safety of IDEC-C2B8 in patients with steroid treatment-resistant pemphigus | steroid treatment-resistant pemphigus | Rituximab (genetic recombination) | Department of Dermatology, Keio University School of Medicine | HOKKAIDO UNIVERSITY HOSPITAL OKAYAMA UNIVERSITY HOSPITAL KURUME UNIVERSITY HOSPITAL | Not Recruiting | 20years-old | 80years-old | Male and Female | 10 | Phase 2 | Japan | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 16 | ChiCTR-OIC-17011759 | 2016-08-01 | 21 August 2017 | pharmacogenomics of Azathioprine induced myelosuppression in the treatment of Pemphigus Vulgaris--study of mutation in TPMT*3 and NUDT15 gene in Chinese people and changes in blood configuration(hemogram). | pharmacogenomics of Azathioprine induced myelosuppression in the treatment of Pemphigus Vulgaris--study of mutation in TPMT*3 and NUDT15 gene in Chinese people and changes in blood configuration(hemogram). | Pemphigus Vulgaris | Case series:Azathioprine; | Dermatological Department, West China hospital, Sichuan University | Not Recruiting | 18 | 65 | Both | Case series:60; | Phase 1 study | China | |
| 17 | EUCTR2015-003564-37-GR | 21/04/2016 | 2 May 2016 | A Pilot Study Investigating the Safety, Clinical Activity, Drug Levels, and Effects on PRN 1008 in Patients with Newly Diagnosed or Relapsing Pemphigus Vulgaris | An Open-Label, Phase 2, Pilot Study Investigating the Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics of Oral Treatment with the BTK Inhibitor PRN1008 in Patients with Newly Diagnosed or Relapsing Pemphigus Vulgaris | Pemphigus: Pemphigus Vulgaris MedDRA version: 18.1 Level: LLT Classification code 10052802 Term: Pemphigus vulgaris System Organ Class: 100000004858 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Code: PRN1008 Pharmaceutical Form: Tablet INN or Proposed INN: Not available CAS Number: 1575596-29-0 Current Sponsor code: PRN1008 Other descriptive name: PRN1008 Freebase Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- INN or Proposed INN: Not available CAS Number: 1575596-29-0 Current Sponsor code: PRN1008 Other descriptive name: PRN1008 Freebase Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 300- INN or Proposed INN: Not available CAS Number: 1575596-30-3 Current Sponsor code: PRN1008 Other descriptive name: PRN1008 Freebase Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- INN or Proposed INN: Not available CAS Number: 1575596-30-3 Current Sponsor code: PRN1008 Other descriptive name: PRN1008 Freebase Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 300- | Principia Biopharma Australia Pty Ltd | Authorised | Female: yes Male: yes | 25 | Phase 2 | France;Greece;Croatia;Australia;Israel | |||
| 18 | EUCTR2015-003564-37-HR | 18/04/2016 | 7 January 2019 | A Pilot Study Investigating the Safety, Clinical Activity, Drug Levels, and Effects on PRN 1008 in Patients with Newly Diagnosed or Relapsing Pemphigus Vulgaris | An Open-Label, Phase 2, Pilot Study Investigating the Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics of Oral Treatment with the BTK Inhibitor PRN1008 in Patients with Newly Diagnosed or Relapsing Pemphigus Vulgaris | Pemphigus: Pemphigus Vulgaris MedDRA version: 20.0 Level: LLT Classification code 10052802 Term: Pemphigus vulgaris System Organ Class: 100000004858 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Code: PRN1008 Pharmaceutical Form: Tablet INN or Proposed INN: Not available CAS Number: 1575596-29-0 Current Sponsor code: PRN1008 Other descriptive name: PRN1008 Freebase Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- INN or Proposed INN: Not available CAS Number: 1575596-29-0 Current Sponsor code: PRN1008 Other descriptive name: PRN1008 Freebase Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 300- INN or Proposed INN: Not available CAS Number: 1575596-30-3 Current Sponsor code: PRN1008 Other descriptive name: PRN1008 Freebase Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- INN or Proposed INN: Not available CAS Number: 1575596-30-3 Current Sponsor code: PRN1008 Other descriptive name: PRN1008 Freebase Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 300- | Principia Biopharma Australia Pty Ltd | Authorised | Female: yes Male: yes | 50 | Phase 2 | France;Greece;Croatia;Australia;Israel | |||
| 19 | NCT02704429 | February 2016 | 28 October 2019 | A Study of PRN1008 in Adult Patients With Pemphigus Vulgaris | An Open-Label, Phase 2, Pilot Study Investigating the Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics of Oral Treatment With the BTK Inhibitor PRN1008 in Patients With Newly Diagnosed or Relapsing Pemphigus Vulgaris | Pemphigus Vulgaris | Drug: PRN1008 | Principia Biopharma Inc. | Principia Biopharma Australia Pty Ltd. | Not recruiting | 18 Years | 80 Years | All | 42 | Phase 2 | Australia;Croatia;France;Greece;Israel |
| 20 | NCT02828163 | January 2016 | 16 December 2017 | Comparison Between Injections of Steroids and Autologous Platelet Rich Plasma in the Oral Erosions of Pemphigus Vulgaris | Comparative Study Between Intralesional Autologous Platelet Rich Plasma and Intralesional Triamcinolone Acetonide in the Oral Erosions of Pemphigus Vulgaris Patients | Oral Pemphigus Vulgaris | Other: Autologous Platelet rich plasma;Drug: Triamcinolone Acetonide | Cairo University | Not recruiting | N/A | N/A | All | 11 | Phase 3 | Egypt | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 21 | NCT02613910 | December 23, 2015 | 16 December 2017 | Long-Term Extension Study of Ofatumumab in Subjects With Pemphigus Vulgaris | OPV117059: A Long-Term Extension Study of Ofatumumab Injection for Subcutaneous Use in Subjects With Pemphigus Vulgaris | Pemphigus | Drug: Ofatumumab;Drug: Acetaminophen/paracetamol;Drug: Antihistamine (cetirizine or equivalent);Drug: Prednisone/Prednisolone | GlaxoSmithKline | Not recruiting | N/A | N/A | All | 1 | Phase 3 | United States | |
| 22 | NCT02383589 | May 26, 2015 | 26 August 2019 | A Study to Evaluate the Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil (MMF) in Participants With Pemphigus Vulgaris (PV) | A Randomized, Double-Blind, Double-Dummy, Active-Comparator, Multicenter Study to Evaluate the Efficacy and Safety of Rituximab Versus MMF in Patients With Pemphigus Vulgaris | Pemphigus Vulgaris | Drug: Mycophenolate Mofetil Placebo;Drug: Mycophenolate Mofetil;Drug: Rituximab;Drug: Rituximab Placebo | Hoffmann-La Roche | Genentech, Inc. | Not recruiting | 18 Years | 75 Years | All | 135 | Phase 3 | United States;Argentina;Australia;Brazil;Canada;France;Germany;Israel;Italy;Spain;Turkey;Ukraine |
| 23 | EUCTR2014-000382-41-DE | 06/03/2015 | 25 June 2018 | A Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil in Patients With Pemphigus Vulgaris | A randomized, double-blind, double-dummy active-comparator, multicenter study to evaluate the efficacy and safety of rituximab versus MMF in patients with pemphigus vulgaris - PEMPHIX | Pemphigus Vulgaris (PV) MedDRA version: 20.0 Level: LLT Classification code 10052802 Term: Pemphigus vulgaris System Organ Class: 100000004858 ;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] | Trade Name: MABTHERA® Product Name: Rituximab Product Code: RO0452294/V02 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: RITUXIMAB CAS Number: 174722-31-7 Current Sponsor code: RO 0452294 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 500mg/50ml- Pharmaceutical form of the placebo: Concentrate for solution for infusion Route of administration of the placebo: Intravenous use Trade Name: CELLCEPT® Product Name: Mycophenolate mofetil Product Code: RO1061443/F02 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Mycophenolate mofetil CAS Number: 128794-94-5 Current Sponsor code: RO1061443/F02 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 500- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use | F. Hoffmann-La Roche Ltd | Authorised | Female: yes Male: yes | 132 | Phase 3 | France;United States;Canada;Argentina;Spain;Ukraine;Turkey;Australia;Israel;Germany;Italy | |||
| 24 | NCT02365675 | January 2015 | 2 March 2015 | Wound Dressings for Pemphigus and Pemphigoid | An Open Randomized Comparative Trial of Four Different Dressings for Cutaneous Coverage in Pemphigus and Pemphigoid | Pemphigus;Pemphigoid | Device: Cotton gauze with petrolatum;Device: Cellulose acetate with petrolatum;Device: Nanocrystalline silver (Acticoat);Device: Carboxymethylcellulose with ionic silver (Aquacel Ag) | Fundación Nacional para la Enseñanza y la Investigación de la Dermatología A.C. | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | Recruiting | 18 Years | N/A | Both | 12 | N/A | Mexico |
| 25 | EUCTR2013-001370-20-IT | 26/11/2014 | 29 August 2016 | Study of subcutaneous Ofatumumab Injections for Pemphigus Vulgaris | OPV116910: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Ofatumumab Injection for Subcutaneous Use in Subjects with Pemphigus Vulgaris | Pemphigus Vulgaris MedDRA version: 17.0 Level: LLT Classification code 10052802 Term: Pemphigus vulgaris System Organ Class: 100000004858 ;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] | Product Name: ofatumumab Product Code: GSK1841157 Pharmaceutical Form: Concentrate for solution for injection INN or Proposed INN: OFATUMUMAB CAS Number: 679818-59-8 Current Sponsor code: GSK1841157 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use | Glaxo Group Ltd | Not Recruiting | Female: yes Male: yes | 136 | Phase 3 | United States;Greece;Ukraine;Israel;Russian Federation;Italy;France;Poland;Croatia;Australia;China;Japan;Korea, Republic of | |||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 26 | JPRN-UMIN000015451 | 2014/11/13 | 2 April 2019 | Exploratory research on effectiveness and safety of Rituximab treatment including maintenance administration for steroid intractable autoimmune bullous diseases of the skin. Rtx-BD Trial (Rituximab of Intractable Autoimmune Bullous Disease Trial) 2 | Pemphigus, Pemphigoid | Rituximab 375mg/sqm, q1w, 4 doses. Maintenance administration of rituximab is possible if PDA or BPDAI is between 1 and 10 on week 24 to 48 | Department of Dermatology, Keio University School of Medicine | Hokkaido University, Kurume University, Okayama University, Kawasaki Medical School | Not Recruiting | 20years-old | 80years-old | Male and Female | 20 | Phase 1,2 | Japan | |
| 27 | JPRN-jRCTs031180220 | 01/05/2014 | 22 July 2019 | Rituximab treatment of blistering disease | Treatment of refractory autoimmuno blistering disease with rituximab | Pemphigus vulgaris, paraneoplastic pemphigus, bullous pemphigoid | Infusion of rituximab (1000mg) intravenously. Approximately two weeks after the first dose, a second dose of rituximab is administered in a similar manner. | Miwa Kanaoka | Aihara Michiko | Recruiting | 20 age old | 80 age old | Both | 10 | N/A | none |
| 28 | NCT01930175 | December 18, 2013 | 28 October 2019 | Study of Efficacy and Safety of VAY736 in Patients With Pemphigus Vulgaris | A Randomized, Partial-blind, Placebo-controlled Trial Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of VAY736 in the Treatment of Patients With Pemphigus Vulgaris | Pemphigus Vulgaris | Drug: VAY736;Drug: Placebo to VAY736 | Novartis Pharmaceuticals | Not recruiting | 20 Years | 70 Years | All | 16 | Phase 2 | United States;Austria;Bulgaria;Taiwan;Germany;Israel;Italy;United Kingdom | |
| 29 | EUCTR2013-001217-33-AT | 25/11/2013 | 19 March 2018 | Study of efficacy and safety of VAY736 in patients with Pemphigus vulgaris | A randomized, partial-blind, placebo-controlled trial evaluating the efficacy, safety, pharmacokinetics and pharmacodynamics of VAY736 in the treatment of patients with pemphigus vulgaris | Pemphigus vulgaris MedDRA version: 20.0 Level: LLT Classification code 10052802 Term: Pemphigus vulgaris System Organ Class: 100000004858 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Code: VAY736 Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: ianalumab Current Sponsor code: VAY736 Concentration unit: mg/kg milligram(s)/kilogram Concentration type: range Concentration number: 3-10 Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use | Novartis Pharma Services AG | Not Recruiting | Female: yes Male: yes | 32 | Phase 2 | United States;Taiwan;Austria;Bulgaria | |||
| 30 | NCT01974518 | November 2013 | 19 February 2015 | Comparative Study of Rituximab Versus Combination of Rituximab and Intravenous Cyclophosphamide in Severe Pemphigus | A PILOT STUDY TO ASSESS THE EFFICACY OF RITUXIMAB VERSUS COMBINATION OF RITUXIMAB AND INTRAVENOUS CYCLOPHOSPHAMIDE IN THE TREATMENT OF REFRACTORY PEMPHIGUS | Pemphigus | Drug: Rituximab and Cyclophosphamide IV | Uprety Shraddha | Postgraduate Institute of Medical Education and Research | Not recruiting | 18 Years | N/A | Both | 20 | Phase 3 | India |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 31 | EUCTR2013-000211-24-DE | 01/10/2013 | 6 January 2015 | immunoglobulin infusion as adjuvant therapy in patients with Pemphigus Vulgaris | A multicenter, randomized, placebo-controlled, double-blind proof of concept study to evaluate the efficacy and safety of the human normal immunoglobulin Intratect® 5% for intravenous use as adjuvant therapy in patients with Pemphigus Vulgaris - IMAT-PV | patients with Pemphigus vulgaris MedDRA version: 16.0 Level: LLT Classification code 10052802 Term: Pemphigus vulgaris System Organ Class: 100000004858 ;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] | Trade Name: Intratect 5% Product Name: Intratect Pharmaceutical Form: Infusion Other descriptive name: WATER FOR INJECTION Concentration unit: ml millilitre(s) Concentration type: up to Concentration number: 1- Other descriptive name: GLYCINE Concentration unit: µmol micromole(s) Concentration type: equal Concentration number: 300- Pharmaceutical form of the placebo: Infusion Route of administration of the placebo: Intravenous use | Ruprecht-Karls-University Heidelberg | Not Recruiting | Female: yes Male: yes | Germany | |||||
| 32 | NCT01920477 | August 13, 2013 | 11 June 2018 | Efficacy and Safety of Ofatumumab in Treatment of Pemphigus Vulgaris | OPV116910: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Ofatumumab Injection for Subcutaneous Use in Subjects With Pemphigus Vulgaris | Pemphigus | Biological: Ofatumumab;Biological: Placebo | Novartis Pharmaceuticals | Not recruiting | 18 Years | 70 Years | All | 35 | Phase 3 | United States;Australia;Croatia;France;Greece;Israel;Italy;Japan;Korea, Republic of;Poland;Romania;Russian Federation;Ukraine | |
| 33 | ChiCTR-TRC-12003539 | 2011-08-01 | 18 April 2017 | Use of Oral Methotrexate plus Glucocorticoid for the Treatment of Pemphigus:A multicenter,randomized and controlled clinincal trial | Guideline-oriented Research in the Management of Some Common and Severe Skin Diseases | Pemphigus | Glucocorticoid hormone group:This group receives systemic glucocorticoid , initially ,with prednisone at 1mg/kg/day. Then we adjust the dose of glucocorticoid according to the patients' responses. ;Glucocorticoids joint methotrexate (MTX) group:This group receives systemic glucocorticoid plus MTX and starts with prednisone at 1mg/kg/day and MTX oral intake at 15mg/week. Then we adjust the dose of glucocorticoid according to the patients' responses. ; | Institute of dermatology, Chinese Academyof Medical Sciences | Not Recruiting | 18 | 75 | Both | Glucocorticoid hormone group:90;Glucocorticoids joint methotrexate (MTX) group:90; | Post-market | China | |
| 34 | ChiCTR-TRC-12003540 | 2011-08-01 | 18 April 2017 | Use of intravenous Methotrexate plus Glucocorticoid for the Treatment of Pemphigus:A multicenter,randomized and controlled clinical trial | Guideline-oriented Research in the Management of Some Common and Severe Skin Diseases | Pemphigus | Glucocorticoid group:This group receives systemic glucocorticoid, initially, with prednisone at 1mg/kg/day.;Glucocorticoid plus MTX group:This group receives systemic glucocorticoid plus MTX and starts with prednisone at 1mg/kg/day and MTX IV drip infusion at 15mg/week. Then we adjust the dose of glucocorticoid according to the patients' responses. ; | Institute of dermatology, Chinese Academyof Medical Sciences | Not Recruiting | 18 | 75 | Both | Glucocorticoid group:90;Glucocorticoid plus MTX group:90; | Post-market | China | |
| 35 | NCT01299857 | June 2011 | 19 February 2015 | Long-term Clinical and Biological Evaluation of Patients With Severe Forms of Pemphigus Treated by Rituximab | EVALUATION CLINIQUE ET BIOLOGIQUE A LONG TERME DES PATIENTS ATTEINTS DE FORMES SEVERES DE PEMPHIGUS TRAITES PAR LE RITUXIMAB | Pemphigus | Drug: Rituximab | University Hospital, Rouen | Not recruiting | 18 Years | N/A | Both | 22 | Phase 3 | France | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 36 | NCT01313923 | February 2011 | 16 December 2017 | Evaluating Sirolimus to Treat Autoimmune Blistering Dermatosis Pemphigus | Evaluation of Sirolimus for the Treatment of the Autoimmune Blistering Dermatosis Pemphigus | Pemphigus | Drug: Sirolimus (formerly known as Rapamycin) | University of California, Irvine | Not recruiting | 18 Years | N/A | All | 3 | Early Phase 1 | United States | |
| 37 | JPRN-UMIN000004428 | 2010/11/01 | 2 April 2019 | Exploratory research on effectiveness and safety of Rituximab treatment for steroid intractable pemphygus, bullous pemphigoid and epidermolysis bullosa acquisita. | pemphigus, bullous pemphigoid, epidermolysis bullosa acquisita | Rituximab | Research group of rare intractable dermatologial disorder | Not Recruiting | 20years-old | Not applicable | Male and Female | 20 | Phase 2 | Japan | ||
| 38 | NCT01338103 | January 2010 | 19 February 2015 | Treatment of Pemphigus Patients With Rituximab 1000mgX2 and Assessment of Immune Status Via Cylex | Treatment of Moderate to Severe Patients With Pemphigus With the Monoclonal Anti CD20 Antibody Rituximab at a Protocol of 1000mgX2 and Assessment of Their Immune Status Via the Cylex Test | Pemphigus | Drug: Rituximab | Rabin Medical Center | Leumit Health Services | Recruiting | 18 Years | 70 Years | Both | 10 | N/A | Israel |
| 39 | NCT00784589 | July 2009 | 16 December 2017 | Comparison Between Rituximab Treatment and General Corticotherapy Treatment in Patients With Pemphigus | Comparison Between Monoclonal Antibody CD20 Treatment (Rituximab (mabthéra))and General Corticotherapy Treatment in Patients With Pemphigus | Pemphigus Disease | Drug: General Corticotherapy;Drug: Rituximab | University Hospital, Rouen | Not recruiting | 18 Years | 80 Years | All | 90 | Phase 3 | France | |
| 40 | NCT00960713 | June 2009 | 19 February 2015 | The RITAI Cohort: An Observational Study on Rituximab Off-label Use for Auto-immune Disorders | The RITAI Cohort. An Observational Study on Serious Adverse Events Occuring After Rituximab Off-label Use for Auto-immune Disorders | Pemphigus;Auto-immune Thrombocytopenic Purpura;Hemolytic Auto-immune Anaemia;Cold Agglutinin Disease;Cryoglobulinemia | Drug: Rituximab (MABTHERA® or RITUXAN®). | University Hospital, Toulouse | Not recruiting | 18 Years | N/A | Both | 35 | N/A | France | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 41 | EUCTR2008-005266-31-FR | 06/02/2009 | 19 March 2012 | COMPARAISON D'UN TRAITEMENT PAR L'ANTICORPS MONOCLONAL ANTI-CD 20 : RITUXIMAB (MABTHERA®) ASSOCIE A UNE CORTICOTHERAPIE GENERALE COURTE PAR RAPPORT A UNE CORTICOTHERAPIE GENERALE DE LONGUE DUREE CHEZ LES PATIENTS ATTEINTS DE PEMPHIGUS - Rituximab III | COMPARAISON D'UN TRAITEMENT PAR L'ANTICORPS MONOCLONAL ANTI-CD 20 : RITUXIMAB (MABTHERA®) ASSOCIE A UNE CORTICOTHERAPIE GENERALE COURTE PAR RAPPORT A UNE CORTICOTHERAPIE GENERALE DE LONGUE DUREE CHEZ LES PATIENTS ATTEINTS DE PEMPHIGUS - Rituximab III | Pemphogoide bulleuse MedDRA version: 9.1 Level: LLT Classification code 10006567 Term: Bullous pemphigoid | Trade Name: mabthéra Product Name: mathéra Pharmaceutical Form: Solution for injection Trade Name: Prednisone Product Name: CORTANCYL 20 mg Pharmaceutical Form: Tablet | CHU-Hôpitaux de Rouen | Authorised | Female: yes Male: yes | France | |||||
| 42 | NCT00626678 | January 2008 | 19 February 2015 | Azathioprine Versus Placebo in Pemphigus Vulgaris Treated With Prednisolone | A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Adjuvant Azathioprine Therapy in New Cases of Pemphigus Vulgaris Receiving Prednisone | Pemphigus Vulgaris | Drug: Azathioprine;Drug: Prednisone;Drug: Placebo | Tehran University of Medical Sciences | Not recruiting | 10 Years | 75 Years | Both | 48 | Phase 2 | Iran, Islamic Republic of | |
| 43 | NCT00656656 | January 2008 | 16 December 2017 | Immunoadsorption, Dexamethasone Pulse Therapy and Rituximab for Pemphigus | Combined Treatment of Autoimmune Bullous Diseases With Protein A Immunoadsorption, Dexamethasone Pulse Therapy and Rituximab | Pemphigus | Drug: Combination of Protein A Immunoadsorption, Rituximab, Dexamethasone plus Azathioprine | University of Luebeck | Not recruiting | 18 Years | N/A | All | 23 | Phase 2 | Germany | |
| 44 | EUCTR2007-005711-26-IT | 15/11/2007 | 19 March 2012 | An open prospective, monocenter, consecutive non randomized clinical trial on therapy with monoclonal antibodies anti-CD20 in the treatment of pemphigus vulgare or foliaceus, serious and resistant to common therapies - ND | An open prospective, monocenter, consecutive non randomized clinical trial on therapy with monoclonal antibodies anti-CD20 in the treatment of pemphigus vulgare or foliaceus, serious and resistant to common therapies - ND | Pemphigus vulgaris, pemphigus foliaceus MedDRA version: 9.1 Level: LLT Classification code 10034280 Term: Pemphigus | Trade Name: MABTHERA Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Rituximab Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- | ISTITUTO DERMOPATICO IMMACOLATA | Authorised | Female: yes Male: yes | Italy | |||||
| 45 | NCT00606749 | November 2007 | 19 February 2015 | Use of KC706 for the Treatment of Pemphigus Vulgaris | A Phase 2 Open-Label Uncontrolled Pilot Study of KC706 in Patients With Stable, Active Pemphigus Vulgaris | Pemphigus Vulgaris | Drug: KC706 | Kemia, Inc | Not recruiting | 18 Years | N/A | Both | 20 | Phase 2 | United States | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 46 | NCT00483119 | April 2007 | 19 October 2017 | Randomized Trial of IVIg With or Without Cyclophosphamide in Pemphigus | Phase 2 Randomized Trial of IVIg With or Without Cyclophosphamide in Pemphigus | Pemphigus Vulgaris | Drug: intravenous immunoglobulin;Drug: cyclophosphamide | New York University School of Medicine | Not recruiting | 18 Years | 85 Years | All | 9 | Phase 2 | United States | |
| 47 | NCT00283712 | March 2006 | 16 December 2017 | Use of Infliximab for the Treatment of Pemphigus Vulgaris | A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Infliximab in Subjects With Pemphigus Vulgaris Receiving Prednisone | Pemphigus | Drug: Infliximab;Other: Placebo Comparator | National Institute of Allergy and Infectious Diseases (NIAID) | Autoimmunity Centers of Excellence | Not recruiting | 18 Years | N/A | All | 20 | Phase 2 | United States |
| 48 | EUCTR2004-000526-75-ES | 06/02/2006 | 19 March 2012 | Estudio multicéntrico, prospectivo, aleatorizado, con doble enmascaramiento, controlado con placebo, de grupos paralelos y 52 semanas de duración para evaluar la eficacia y la seguridad del micofenolato mofetilo (MMF) como tratamiento complementario para conseguir remisión con una dosis reducida de corticosteroides en pacientes con pénfigo vulgar - Seguridad y Eficacia de micofenolato mofetilo en Pemphigus Vulgaris | Estudio multicéntrico, prospectivo, aleatorizado, con doble enmascaramiento, controlado con placebo, de grupos paralelos y 52 semanas de duración para evaluar la eficacia y la seguridad del micofenolato mofetilo (MMF) como tratamiento complementario para conseguir remisión con una dosis reducida de corticosteroides en pacientes con pénfigo vulgar - Seguridad y Eficacia de micofenolato mofetilo en Pemphigus Vulgaris | Pénfigo vulgar MedDRA version: 8.1 Level: LLT Classification code 10052802 | Trade Name: CellCept®500 mg comprimidos Product Name: CellCept 500 mg comprimidos recubiertos Pharmaceutical Form: Tablet INN or Proposed INN: micofenolato mofetilo Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 500- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use | Aspreva pharmaceuticals Corporation | Authorised | Female: yes Male: yes | 72 | Spain | ||||
| 49 | NCT00135720 | June 2004 | 29 June 2015 | Study of Etanercept (Enbrel) in the Treatment of Pemphigus Vulgaris | A Double-Blinded, Placebo-Controlled Study of Etanercept (Enbrel) in the Treatment of Pemphigus Vulgaris | Pemphigus Vulgaris | Drug: Enbrel (Etanercept) | Massachusetts General Hospital | Brigham and Women's Hospital;Stanford University | Not recruiting | 18 Years | 65 Years | Both | 12 | Phase 2 | United States |
| 50 | NCT00683930 | May 2004 | 19 October 2017 | A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Patients With Active Pemphigus Vulgaris (PV) | A Prospective, Randomised, Double-blind, Placebo-controlled, Parallel Group, Mult-center, 52-week Trial to Assess the Efficacy and Safety of Adjunct Mycophenolate Mofetil (MMF) to Achieve Remission With Reduced Corticosteroid in Subjects With Pemphigus Vulgaris | Pemphigus Vulgaris (PV) | Drug: Mycophenolate Mofetil 2 g/Day;Drug: Mycophenolate Mofetil (MMF) 3 g/Day;Drug: Placebo | Hoffmann-La Roche | Aspreva Pharmaceuticals | Not recruiting | 18 Years | 70 Years | All | 96 | Phase 3 | United States;Canada;Germany;Israel;Switzerland;Turkey;Ukraine;United Kingdom;India |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 51 | NCT00063752 | July 2003 | 19 February 2015 | Safety Study of PI-0824 to Treat Pemphigus Vulgaris | An Open-Label, Dose-Escalation, Phase I Clinical Study to Assess the Safety of PI-0824 in Patient With Pemphigus Vulgaris Requiring Daily Corticosteroid Therapy | Pemphigus Vulgaris | Drug: PI-0824 | Peptimmune | Not recruiting | 18 Years | N/A | Both | 15 | Phase 1 | United States | |
| 52 | NCT00213512 | June 2003 | 19 February 2015 | Effect of Anti CD20 in Pemphigus Desease | Traitment of Patients Presenting Pemphigus With Anti CD20 (Mabthera). | Pemphigus | Drug: Mabthera | University Hospital, Rouen | Not recruiting | 18 Years | N/A | Both | 22 | Phase 2/Phase 3 | France | |
| 53 | NCT00278642 | September 2002 | 19 February 2015 | Hematopoietic Stem Cell Support in Patients With Autoimmune Bullous Skin Disorders | High Dose Cyclophosphamide & ATG With Hematopoietic Stem Cell Support in Patients With Autoimmune Bullous Skin Disorders: A Phase I Trial | Pemphigus | Biological: Hematopoietic stem cell transplantation | Richard Burt, MD | Not recruiting | 18 Years | 60 Years | Both | 1 | Phase 1 | United States | |
| 54 | NCT00213421 | August 2001 | 19 February 2015 | Comparison of Two Therapeutic Strategies of Dermoval in Treatment of Bullous Pemphigus | Bullous Pemphigoid | Drug: Dermoval | University Hospital, Rouen | Not recruiting | 18 Years | N/A | Both | 330 | Phase 4 | France | ||
| 55 | NCT00127764 | January 2001 | 19 February 2015 | European Trial of Adjuvant Oral Glucocorticoid Pulse Therapy in Pemphigus | European Randomised Placebo-Controlled Trial of Adjuvant Oral Glucocorticoid Pulse Therapy in Pemphigus (Pempuls Trial) | Pemphigus | Drug: dexamethasone (50mg 1dd6, 3 consecutive days/month) | University Medical Centre Groningen | Not recruiting | 18 Years | N/A | Both | 60 | Phase 2/Phase 3 | Netherlands | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 56 | NCT00010413 | April 1999 | 19 February 2015 | Phase II Study of High-Dose Cyclophosphamide in Patients With Refractory Pemphigus | Pemphigus | Drug: cyclophosphamide;Drug: filgrastim | Johns Hopkins University | Not recruiting | 18 Years | 70 Years | Both | 35 | Phase 2 | United States | ||
| 57 | NCT00429533 | November 1996 | 19 February 2015 | Efficacy of Dapsone as a Steroid Sparing Agent in Pemphigus Vulgaris | A Prospective Randomized Placebo-Controlled Clinical Trial of Dapsone as a Glucocorticoid-Sparing Agent in Maintenance Phase Pemphigus Vulgaris | Pemphigus Vulgaris | Drug: Dapsone | Jacobus Pharmaceutical | Not recruiting | 18 Years | 80 Years | Both | 48 | Phase 2 | United States |